By otakuyassine3@gmail.com 
Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 2,570,000 shares, a growth of 14.7% from the December 15th total of 2,240,000 shares. Based on an average daily volume of 883,200 shares, the short-interest ratio is presently 2.9 days.
Axon Enterprise Price Performance
NASDAQ AXON traded up $8.05 on Friday, hitting $593.89. The stock had a trading volume of 533,566 shares, compared to its average volume of 1,040,913. The firm has a 50-day moving average of $617.37 and a 200-day moving average of $458.84. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a 52-week low of $247.04 and a 52-week high of $698.67. The company has a market capitalization of $45.28 billion, a price-to-earnings ratio of 153.46, a price-to-earnings-growth ratio of 5.71 and a beta of 1.04.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on AXON. Robert W. Baird raised their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Needham & Company LLC boosted their target price on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Northland Securities boosted their price objective on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, TD Cowen assumed coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price for the company. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $504.92.
Read Our Latest Research Report on Axon Enterprise
Insiders Place Their Bets
In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the transaction, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeffrey C. Kunins sold 1,035 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $624.47, for a total value of $646,326.45. Following the sale, the insider now directly owns 124,243 shares of the company’s stock, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,545 shares of company stock valued at $30,721,337. Corporate insiders own 5.70% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in Axon Enterprise by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,782,828 shares of the biotechnology company’s stock worth $710,103,000 after buying an additional 35,320 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares in the last quarter. Champlain Investment Partners LLC increased its position in shares of Axon Enterprise by 13.9% in the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after purchasing an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Axon Enterprise by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after purchasing an additional 9,090 shares in the last quarter. Finally, Groupama Asset Managment bought a new stake in Axon Enterprise during the third quarter valued at approximately $200,000. Institutional investors own 79.08% of the company’s stock.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.